NASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis $71.70 -0.27 (-0.38%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$71.69 -0.01 (-0.01%) As of 08/14/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PTC Therapeutics Stock (NASDAQ:PTCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTC Therapeutics alerts:Sign Up Key Stats Today's Range$70.85▼$72.1350-Day Range$68.01▼$89.5752-Week Range$47.94▼$90.87Volume564,330 shsAverage Volume1.21 million shsMarket Capitalization$5.98 billionP/E RatioN/ADividend YieldN/APrice Target$98.55Consensus RatingModerate Buy Company Overview PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options. Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets. The company also commercializes Emflaza (deflazacort) for patients with Duchenne muscular dystrophy, expanding its portfolio in neuromuscular disease. PTC’s pipeline extends into areas such as central nervous system disorders and metabolic diseases, with programs advancing through clinical and preclinical stages to address rare forms of Rett syndrome, tyrosinemia and other genetic conditions. Headquartered in South Plainfield, New Jersey, PTC operates a global network encompassing commercial, research and manufacturing facilities across North America, Europe and Asia. The company’s leadership team is led by Stuart W. Peltz, Ph.D., who has served as Chief Executive Officer since co-founding the business. Under his guidance, PTC has established strategic collaborations and regulatory approvals that bolster its presence in key international markets, reflecting a commitment to bringing innovative therapies to patients around the world.AI Generated. May Contain Errors. Read More PTC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePTCT MarketRank™: PTC Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 177th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingPTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 9 buy ratings, 2 hold ratings, and 2 sell ratings.Upside PotentialPTC Therapeutics has a consensus price target of $98.55, representing about 37.4% upside from its current price of $71.70.Amount of Analyst CoveragePTC Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PTC Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth82.05% Earnings GrowthEarnings for PTC Therapeutics are expected to grow by 82.05% in the coming year, from $1.17 to $2.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -123.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -123.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioPTC Therapeutics has a PEG Ratio of 2.21. PEG Ratios above 1 indicate that a company could be overvalued.Read more about PTC Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.37% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 7.52.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 7.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.30 News SentimentPTC Therapeutics has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for PTC Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,654,065.00 in company stock.Percentage Held by Insiders5.30% of the stock of PTC Therapeutics is held by insiders.Percentage Held by InstitutionsPTC Therapeutics has minimal institutional ownership at this time.Read more about PTC Therapeutics' insider trading history. Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTCT Stock News HeadlinesPTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study TranscriptAugust 13 at 4:00 AM | seekingalpha.comPTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease ProgramAugust 12, 2026 | prnewswire.comBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.August 16 at 1:00 AM | TradeSmith (Ad)PTC Therapeutics (NASDAQ:PTCT) CEO Sells 10,292 SharesAugust 7, 2026 | insidertrades.comMorgan Stanley Keeps Their Buy Rating on PTC Therapeutics (PTCT)August 3, 2026 | theglobeandmail.comWells Fargo Sticks to Their Buy Rating for PTC Therapeutics (PTCT)August 3, 2026 | theglobeandmail.comPTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call TranscriptJuly 30, 2026 | seekingalpha.comPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsJuly 30, 2026 | prnewswire.comSee More Headlines PTCT Stock Analysis - Frequently Asked Questions How have PTCT shares performed this year? PTC Therapeutics' stock was trading at $75.96 on January 1st, 2026. Since then, PTCT shares have decreased by 5.6% and is now trading at $71.70. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Thursday, July, 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.24 by $0.68. PTC Therapeutics's revenue was up 101.5% compared to the same quarter last year. Read the conference call transcript. When did PTC Therapeutics IPO? PTC Therapeutics (PTCT) raised $121 million in an initial public offering (IPO) on Thursday, June 20th 2013. The company issued 8,372,000 shares at a price of $13.00-$16.00 per share. Who are PTC Therapeutics' major shareholders? PTC Therapeutics' top institutional investors include BlackRock Inc. (16.73%), Jupiter Topco LLC (8.67%), William Blair Investment Management LLC (2.06%) and The Manufacturers Life Insurance Company (0.53%). Insiders that own company stock include Matthew B Klein, Michael Schmertzler, Mark Elliott Boulding, Pierre Gravier, Lee Scott Golden, Eric Pauwels, Christine Marie Utter, Neil Gregory Almstead, Mary L Smith, Glenn Md Phd Steele Jr, Allan Steven Jacobson, David P Southwell, Jerome B Zeldis, Emma Reeve, Alethia Young and Stephanie Okey. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD). Company Calendar Last Earnings7/30/2026Today8/16/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 12 days, PTCT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PTCT CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year Founded1998Price Target and Rating Average Price Target for PTC Therapeutics$98.55 High Price Target$130.00 Low Price Target$50.00 Potential Upside/Downside+37.4%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E Ratio61.28 P/E Growth2.21Net Income$682.64 million Net Margins-3.80% Pretax Margin-6.65% Return on Equity-362.45% Return on Assets-1.32% Debt Debt-to-Equity RatioN/A Current Ratio3.39 Quick Ratio3.28 Sales & Book Value Annual Sales$1.73 billion Price / Sales3.46 Cash Flow$8.78 per share Price / Cash Flow8.17 Book Value($1.98) per share Price / Book-36.21Miscellaneous Outstanding Shares83,460,000Free Float79,038,000Market Cap$5.98 billion OptionableOptionable Beta0.56 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PTCT) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredA Dark Day Is Coming to AmericaKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredWhat is Trump’s decade-long obsession?No president has moved markets like Trump, adding and erasing trillions in value seemingly at will. Analyst...Brownstone Research | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredElon admits defeatElon Musk just called Anthropic the clear leader in AI, admitting its Mythos model surpasses anything he's bui...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
